drugset / Trial / NCT04151810
Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The main purpose of this study was to evaluate the safety and tolerability of CDP1 in patients with advanced solid tumor, to explore dose limited toxicity (DLT), and to determine the recommended dose (RP2D) for phase II clinical trials.
Timeline
- Start
- 2019-12-16
- Primary completion
- 2022-10-13
- Completion
- 2022-10-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CDP1 | Monoclonal antibody | 250 mg/m2 | — |
| Subject | CDP1 | Monoclonal antibody | 400 mg/m2 | — |
| Subject | CDP1 | Monoclonal antibody | 500 mg/m2 | — |
| Subject | CDP1 | Monoclonal antibody | 750 mg/m2 | — |
| Background | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Background | Ifosfamide | Small molecule | 1200 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | — |
Indications
No indication recorded.